The latest announcement is out from KalVista Pharmaceuticals (KALV).
William Fairey has been appointed to the Board of Directors, effective immediately, with a term expiring at the Company’s 2024 Annual Meeting of Stockholders. His appointment, recommended by the Nominating and Governance Committee, does not stem from any prior arrangements or undisclosed transactions. Fairey meets the independence criteria of the Nasdaq and SEC, and his compensation aligns with the policy for non-employee directors, including stock option awards and cash retainer. The Company announced his appointment in a recent press release.
For an in-depth examination of KALV stock, go to TipRanks’ Stock Analysis page.
